NasdaqGS:DAWNBiotechs
Why Day One Biopharmaceuticals (DAWN) Is Up 39.0% After New OJEMDA Data from FIREFLY-1 Trial
Day One Biopharmaceuticals announced it will present updated OJEMDA durability and clinical stability data from the registrational FIREFLY-1 trial at the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology, with over 36 months of follow-up in pediatric low-grade glioma patients harboring BRAF alterations.
The anticipation centers on new long-term clinical results and regulatory momentum for tovorafenib, highlighted by its Breakthrough Therapy, Rare Pediatric Disease, and...